Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD-Reference-Cited by-同舟云学术

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD

Published:2022-02 Issue:2 Volume:7 Page:270-281
ISSN:2468-0249
Container-title:Kidney International Reports
language:en
Short-container-title:Kidney International Reports

Author:

Higashihara Eiji,Nutahara Kikuo,Itoh Masayuki,Okegawa Takatsugu,Tambo Mistuhiro,Yamaguchi Tsuyoshi,Nakamura Yu,Taguchi Satoru,Kaname Shinya,Yokoyama Kenichi,Yoshioka Tatsuya,Fukuhara Hiroshi

Publisher

Elsevier BV

Subject

Nephrology

Reference39 articles.

1. Volume progression in polycystic kidney disease;Grantham;N Engl J Med,2006

2. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease;Chapman;Clin J Am Soc Nephrol,2012

3. Kidney volume and function in autosomal dominant polycystic kidney disease;Higashihara;Clin Exp Nephrol,2014

4. Autosomal dominant polycystic kidney disease;Torres;Lancet,2007

5. Osmoregulation, vasopressin, and cAMP signaling in autosomal dominant polycystic kidney disease;Devuyst;Curr Opin Nephrol Hypertens,2013

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Juxtaglomerular apparatus-mediated homeostatic mechanisms: therapeutic implication for chronic kidney disease;Expert Opinion on Pharmacotherapy;2024-05-02

2. Genetic Analysis of Severe Polycystic Liver Disease in Japan;Kidney360;2024-05-01

3. Treatment for patients with autosomal dominant polycystic kidney disease in the chronic kidney disease without kidney replacement therapy in real-world clinical practice: a descriptive retrospective cohort study;Annals of Clinical Epidemiology;2024

4. Non-contrast low-dose CT can be used for volumetry of ADPKD;BMC Nephrology;2023-10-26

5. Public support for patients with intractable diseases in Japan: impact on clinical indicators from nationwide registries in patients with autosomal dominant polycystic kidney disease;Clinical and Experimental Nephrology;2023-06-27